UnknownPhase 3NCT05754450

An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II

Studying Leukocyte adhesion deficiency

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AUG Therapeutics
Principal Investigator: David Deyle, MD
Mayo Clinic
Intervention: AVTX-803(drug)
Enrollment: 2 enrolled
Eligibility: 75 years · All sexes
Timeline: 2023 – 2024

Study locations (1)

Mayo Clinic, Rochester, Minnesota, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05754450 on ClinicalTrials.gov

Other trials for Leukocyte adhesion deficiency

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGNCT06282432
Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)
Rocket Pharmaceuticals Inc.

See all trials for Leukocyte adhesion deficiency →

← Back to all trials